Recent Updates
Recently added Catalysts

CTX-10726

Phase 1

Gastroesophageal Cancer (GC) | Small molecule | Oncology |Compass Therapeutics, Inc.|Last Updated: Jun 5, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDBiomarker
Total Trials1
Total Enrollment70
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07419841A Phase 1 Study of the Safety and Tolerability of CTX-10726PHASE1 RECRUITING 70 — — May 28, 2026Nov 1, 2028Jun 5, 20265 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Cohort 1: Evaluate the safety and tolerability of CTX-10726 by incidence of treatment-emergent adverse events (TEAEs) in escalating doses
From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-10726, average of 6 months)

Incidence of dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities.

Cohort 1: Determine the dose(s) of CTX-10726 to be further examined in Cohort 2 and Phase 2 studies
From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks ) until 30 days after the last dose of CTX-10726 (average of 6 months)
Cohort 2: Evaluate the safety and tolerability of CTX-10726 by incidence of treatment-emergent adverse events (TEAEs) at dose(s) selected from Cohort 1
From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-10726 (up to 2 years)

Incidence of treatment-emergent adverse events (TEAEs)

Secondary Endpoints
Objective Response Rate (ORR) (Percentage of Participants With Objective Response) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Baseline until confirmed disease progression (up to 2 years)
Duration of Response (DOR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
From the date of first confirmed complete response (CR) or partial response (PR) until the first date of recurrent or progressive disease (up to 2 years)
Disease Control Rate (DCR) percentage of patients with best overall response of CR, PR, or SD as per RECIST version 1.1
From first dose of CTX-10726(Cycle 1 Day 1,Cycle = 2 weeks ) until disease progression or death, whichever occur first (up to 2 years)
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Dose Escalation Cohort 1EXPERIMENTALEscalating doses of CTX-10726
Dose Expansion Cohort 2EXPERIMENTALDose of CTX-10726 depending on Cohort 1 data
Interventions
NameTypeDescription
CTX-10726DRUGIntravenous (IV) infusion (0.3-10.0mg/kg) every two weeks.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: 1. Age 18 years or older. 2. Patients must have a histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic disease that is relapsed/refractory to standard therapy or for which no effective standard therapy is available, including: 2a: R...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJun 5, 2026NCT07419841lastUpdatePostDate: changed
LOWJun 5, 2026NCT07419841lastUpdatePostDate: changed
LOWJun 5, 2026NCT07419841lastUpdatePostDate: changed
LOWJun 5, 2026NCT07419841lastUpdatePostDate: changed
LOWMay 29, 2026NCT07419841startDate: changed
LOWMay 29, 2026NCT07419841startDate: changed
LOWMay 29, 2026NCT07419841startDate: changed
LOWMay 26, 2026NCT07419841Status: NOT_YET_RECRUITING → RECRUITING
LOWMay 24, 2026NCT07419841studyFirstPostDate: changed